New drug trial aims to shield transplant patients from dangerous immune attack
NCT ID NCT06271616
Summary
This study is testing if a drug called ibrutinib can prevent chronic graft-versus-host disease (GVHD) in adults who have received a donor stem cell transplant. GVHD is a condition where the donor's immune cells attack the patient's body. Researchers want to see if taking ibrutinib daily for about a year after the transplant can stop this harmful immune reaction from developing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224-9980, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.